Brief: Jiangsu Recbio Technology Received Clinical Trial Approval For Its Recombinant Protein Covid-19 Vaccine, Recov From China's NMPA
02/05/2022 15:04
May 2 (Reuters) - Jiangsu Recbio Technology Co Ltd
2179.HK :
* RECEIVED CLINICAL TRIAL APPROVAL FOR ITS RECOMBINANT
PROTEIN
COVID-19 VACCINE, RECOV FROM CHINA'S NMPA
Further company coverage: 2179.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Jiangsu Recbio Technology
See all newsBrief: Jiangsu Recbio Technology To Re-Plan Timetable For HPV Vaccine Marketing Application
Brief: Jiangsu Recbio Technology Says New Drug Application For REC610 Shingles Vaccine Accepted By NMPA
Brief: Jiangsu Recbio Technology Says Liu Yong Resigned As Chair
Brief: Jiangsu Recbio Technology Says Li Bu Resigned As Executive Director
Brief: Jiangsu Recbio Technology Says Acceptance By CSRC Of Application Materials For Issuance Of Shares